Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Juliusson Gunnar) > Subcutaneous cladri...

Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients

Allen-Philbey, Kimberley (författare): Royal London Hospital

De Trane, Stefania (författare): Queen Mary University

Mao, Zhifeng (författare): Guangzhou Medical University

visa fler...

Álvarez-González, Cesar (författare): University Hospital Basel

Mathews, Joela (författare): Royal London Hospital

MacDougall, Amy (författare): London School of Hygiene and Tropical Medicine

Stennett, Andrea (författare): Royal London Hospital

Zhou, Xia (författare): Royal London Hospital

Yildiz, Ozlem (författare): Royal London Hospital

Adams, Ashok (författare): Royal London Hospital

Bianchi, Lucia (författare): Queen Mary University

Blain, Camilla (författare): St George's Hospital, London

Chapman, Christine (författare): Queen Mary University

Chung, Karen (författare): National Hospital for Neurology and Neurosurgery

Constantinescu, Cris S. (författare): Nottingham University Hospitals NHS Trust

Dalton, Catherine (författare): St George's Hospital, London

Farrell, Rachel A. (författare): National Hospital for Neurology and Neurosurgery

Fisniku, Leonora (författare): Brighton and Sussex University Hospitals NHS Trust

Ford, Helen (författare): Leeds Teaching Hospitals NHS Trust

Gran, Bruno (författare): Nottingham University Hospitals NHS Trust

Hobart, Jeremy (författare): Plymouth University, Peninsula Schools of Medicine and Dentistry

Khaleeli, Zhaleh (författare): National Hospital for Neurology and Neurosurgery

Mattoscio, Miriam (författare): Barking, Havering and Redbridge Hospital NHS Trust,Imperial College London

Pavitt, Sue (författare): University of Leeds

Pearson, Owen (författare): Swansea Bay University Health Board

Peruzzotti-Jametti, Luca (författare)

Scalfari, Antonio (författare): Charing Cross Hospital

Sharrack, Basil (författare): Sheffield Teaching Hospitals

Silber, Eli (författare): King's College Hospital

Tallantyre, Emma C. (författare): University Hospital of Wales

Webb, Stewart (författare): Queen Elizabeth University Hospital, Glasgow

Turner, Benjamin P. (författare): Royal London Hospital

Marta, Monica (författare): Royal London Hospital

Gnanapavan, Sharmilee (författare): Royal London Hospital

Juliusson, Gunnar (författare): Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital

Giovannoni, Gavin (författare): Royal London Hospital

Baker, David (författare): Queen Mary University

Schmierer, Klaus (författare): Queen Mary University,Royal London Hospital

visa färre...

(creator_code:org_t)

2021-11-25
2021
Engelska.
Ingår i: Therapeutic Advances in Neurological Disorders. - : SAGE Publications. - 1756-2856 .- 1756-2864. ; 14

Relaterad länk:: http://dx.doi.org/10... (free); visa fler...; https://journals.sag...; https://lup.lub.lu.s...; https://doi.org/10.1...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak®) in multiple sclerosis (MS) patients. Methods: Litak® was offered to MS-patients irrespective of disease course. Litak® 10 mg was administered for 3–4 days during week 1. Based on lymphocyte count at week 4, patients received another 0–3 doses at week 5. A second course was administered 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg and Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA), no-evidence-of-progression-or-active-disease (NEPAD), MRI, cerebrospinal fluid (CSF) neurofilament light chain (NfL), and lymphocyte counts. Results: In all, 208 patients received at least one course of treatment. Age at baseline was 44 (17–72) years and EDSS 0–8.5. Cladribine was generally well tolerated. One myocardial infarction, one breast cancer, and three severe skin reactions occurred without long-term sequelae. Two patients died (one pneumonia, one encephalitis). Lymphopenia grade 3 occurred in 5% and grade 4 in 0.5%. In 94 out of 116 pwMS with baseline and follow-up (BaFU) data after two treatment courses, EDSS remained stable or improved. At 18 months, 64% of patients with relapsing MS and BaFU data (n = 39) had NEDA. At 19 months, 62% of patients with progressive MS and BaFU data (n = 13) had NEPAD. Of n = 13 patients whose CSF-NfL at baseline was elevated, 77% were normalised within 12 months. Conclusions: Litak® was well tolerated. Effectiveness in relapsing MS appeared similar to cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be safe and effective in MS-patients irrespective of their disease stage.

Hitta via bibliotek

Therapeutic Advances in Neurological Disorders (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Artiklar i publikationen: Therapeutic Adva ...

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Subcutaneous cladribine to treat multiple sclerosis : experience in 208 patients

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub